Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Raza Azra, Galili Naomi, Mulford Deborah, Smith, Brown, Steensma, Lyons, Boccia Ralph, Sekeres, Garcia-Manero Guillermo, Mesa